Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:17:25 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Z:MTNB - MATINAS BIOPHARMA HOLDINGS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MTNB - Z0.10.1626·0.21210.10.1789-0.0013-0.71,479.32197880.1875  0.188  0.17480.89  0.110319:03:48Apr 0315 min RT 2¢

Recent Trades - Last 10 of 788
Time ETExPriceChangeVolume
19:03:48Z0.1793-0.00225,100
19:02:21Z0.18870.007250,000
17:50:54Z0.1798-0.001715,000
17:23:52Z0.1798-0.00171,244
17:18:47Z0.18-0.00154,900
17:18:47Z0.1802-0.001321
16:50:04Z0.1808-0.000795
16:45:28Z0.1801-0.00141
16:41:54Z0.1802-0.0013500
16:33:28Z0.1801-0.0014200

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-03 08:30U:MTNBNews ReleaseMatinas BioPharma Prices $10 Million Registered Direct Offering
2024-03-27 16:05U:MTNBNews ReleaseMatinas BioPharma Reports 2023 Financial Results and Provides a Business Update
2024-03-25 08:00U:MTNBNews ReleaseMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
2024-03-22 09:15U:MTNBNews ReleaseThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
2024-03-22 06:30U:MTNBNews ReleaseMatinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
2024-02-26 08:00U:MTNBNews ReleaseMatinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
2024-02-20 07:30U:MTNBNews ReleaseMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
2024-01-03 07:00U:MTNBNews ReleaseMatinas BioPharma to Present at Biotech Showcase 2024
2023-12-27 07:30U:MTNBNews ReleaseMatinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
2023-12-21 07:30U:MTNBNews ReleaseMatinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
2023-11-08 16:05U:MTNBNews ReleaseMatinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
2023-11-07 07:30U:MTNBNews ReleaseMatinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
2023-11-01 07:00U:MTNBNews ReleaseMatinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
2023-10-11 07:30U:MTNBNews ReleasePatient with Candida krusei Infection in Matinas BioPharma ¢ € ™s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
2023-09-28 07:00U:MTNBNews ReleaseMatinas BioPharma to Present at Two Investment Conferences in October 2023
2023-09-27 07:00U:MTNBNews ReleaseMatinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
2023-09-22 17:25U:MTNBNews ReleaseMatinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
2023-09-06 07:00U:MTNBNews ReleaseMatinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
2023-08-22 07:30U:MTNBNews ReleaseMatinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
2023-08-09 16:05U:MTNBNews ReleaseMatinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update